Insight Molecular Diagnostics (IMDX) Cash from Operations (2015 - 2026)

Insight Molecular Diagnostics has reported Cash from Operations for 12 years, with the latest figure at 7639000.0 in Q1 2026.

• Quarterly Cash from Operations fell 30.83% year-over-year to 7639000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 23984000.0 (down 5.67% YoY) and the FY2025 annual result came in at 22184000.0, down 7.23% from the prior year.
• Cash from Operations eased to 7639000.0 in Q1 2026 per IMDX's latest filing, from 5545000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 3769000.0 in Q3 2023 and troughed at 13277000.0 in Q1 2022.
• A 5-year average of 7023823.53 and a median of 5978000.0 in 2024 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations surged 66.93% in 2023, then plunged 52.45% in 2025.
• Over 5 years, Cash from Operations stood at 9648000.0 in 2022, then soared by 54.15% to 4424000.0 in 2023, then decreased by 20.95% to 5351000.0 in 2024, then decreased by 3.63% to 5545000.0 in 2025, then slumped by 37.76% to 7639000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 7639000.0, 5545000.0, and 4502000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.